Braxia Scientific Corp. BRAX BRAXF, a Toronto-based psychedelics company, is launching a randomized clinical trial using psilocybin for adults with treatment-resistant depression.
A number of organizations and for-profit companies in the psychedelics space are looking at the clinical applications of psilocybin in the treatment of depression, including the Usona Institute and Compass Pathways CMPS.
However, according to Braxia, this trial will have wider inclusion criteria than other similar studies.
"This will be the broadest study of its kind," said Dr. Joshua Rosenblat, medical director of the Canadian Rapid Treatment Centre of Excellence Inc., a wholly-owned subsidiary of Braxia Scientific where the study will be held.
"Whereas most other treatment-resistant depression studies limit participation to patients that have not found relief from a maximum of five other potential remedies, our research will not have an upper limit, and will even include patients that have endured dozens of unsuccessful medical trials, including ketamine and electroconvulsive therapy,” Rosenblat said.
The trial will also include patients with more than two failed medical trials, as well as patients with bipolar depression.
Further details on the study's patient base, end goals and dates have not yet been public.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Missed the first wave of cannabis investments? Don’t make that mistake again.
Experts believe cannabis stocks have found their floor and are now poised for unprecedented growth.
Join Benzinga PotProfits. Our in-house canna stock expert, Michael Berger, is on a mission to uncover the most promising cannabis stocks poised for growth, even in a dull market. He leaves no bud unturned to bring you the juiciest potential double-digit opportunities!
Just this year, the PotProfits portfolio has seen smoking-hot gains like:
- 47.10% with $GTBIF
- 40.23% with $TCNNF
- 21.50% with $VFF